35 stories found
Cathie Wood's ARK Invest has made recent changes to its portfolio, including selling Palantir stock and acquiring shares in SpaceX. This comes as questions arise about the performance of other ARK holdings like CRISPR Therapeutics.
Cathie Wood's ARK Invest has made a significant $362 million bet on CRISPR Therapeutics, with analysts suggesting the investment is supported by a catalyst that many investors are currently underrating. This highlights a bold investment strategy in the biotech sector.
An analysis compares gene-editing focused CRISPR Therapeutics with weight-loss focused Viking Therapeutics to determine which stock might be a better investment by 2026.
Despite possessing $2.4 billion in cash and an approved drug, CRISPR Therapeutics' stock is trading nearly 40% below Wall Street's consensus, raising questions among investors.
An analysis highlights a key aspect of CRISPR Therapeutics that investors may be overlooking, suggesting it could be a significant factor in the company's future performance.
CRISPR Therapeutics AG (CRSP) has released its financial results for the first quarter of 2026, detailing its performance and operational updates.
CRISPR Therapeutics (CRSP) has been rated 'Overweight' by analysts, reflecting positive sentiment regarding the company's growth prospects in gene editing.
CRISPR Therapeutics announced $116 million in revenue for fiscal year 2025, primarily attributed to the growth of its gene-editing therapy, CASGEVY.
Several financial firms have issued new ratings, price targets, or coverage initiations for biotech and pharmaceutical companies including Beam Therapeutics, Krystal Biotech, 4D Molecular Therapeutics, BioMarin Pharmaceutical, Vertex Pharmaceuticals, CRISPR Therapeutics AG, Regeneron Pharmaceuticals, and UniQure.
An analysis explores whether CRISPR Therapeutics shares are a good investment opportunity for February.
A list of stocks including Palantir (PLTR), CRISPR Therapeutics (CRSP), and Diamondback Energy (FANG) are highlighted for investors to watch during after-hours trading on Monday.
An article outlines three compelling reasons why investors might consider purchasing shares of CRISPR Therapeutics.
Ondas Holdings is reportedly set to acquire DZYNE Technologies, a maker of autonomous aircraft, in a deal valued at $875.8 million. This acquisition marks a significant move in the autonomous technology sector.
CRISPR Therapeutics AG (CRSP) is listed as one of the most shorted mid-cap stocks recommended for purchase, owing to its robust gene editing pipeline. The company's strong research and development efforts are seen as a key growth driver.
An analysis compares CRISPR Therapeutics and Editas Medicine to determine which gene editing stock presents a better investment opportunity in 2026. The article evaluates their potential for investors.
A top Wall Street analyst has issued a highly bullish forecast for CRISPR Therapeutics, suggesting the company's stock could more than double. The report encourages investors to consider a strong buy position.
An analysis evaluates whether CRISPR Therapeutics stock currently presents a bargain buying opportunity for investors.
CRISPR Therapeutics has priced an upsized convertible debt offering totaling $550 million.
Crispr Therapeutics' stock saw gains following market speculation about a potential takeover of the company.
Several financial firms, including Wedbush, Needham, Evercore ISI, and TD Cowen, have updated their price targets for a range of companies, reflecting revised market outlooks and company performance expectations.
Morgan Stanley has nearly doubled its price target for CRISPR Therapeutics, prompting questions on whether the gene-editing stock is a compelling buy.
CRISPR Therapeutics is highlighted for having over two billion reasons to be considered a promising investment right now, indicating strong market confidence or potential for growth.
An analysis compares CRISPR Therapeutics AG and Vertex Pharmaceuticals to determine which healthcare stock presents a better investment opportunity for 2026. The evaluation focuses on their respective market positions and future prospects.
CRISPR Therapeutics stock is considered to be significantly undervalued, with analysts projecting a substantial upside potential of 437%.
CRISPR Therapeutics (CRSP) is being highlighted as an under-the-radar stock with significant upside potential for 2026, drawing investor interest in the gene-editing sector.
An article highlights reasons to be optimistic about CRISPR Therapeutics, suggesting significant potential or value in the company.
An article analyzes Crispr Therapeutics (CRSP) to determine if it is a top gene-editing stock for investment.
Investor Cathie Wood has reportedly bought the dip in gene-editing firm CRISPR Therapeutics, indicating confidence in the company's future despite recent market movements.
CRISPR Therapeutics' stock experienced a decline following the announcement of a $350 million convertible debt offering.
An analysis questions the risk associated with investing in CRISPR Therapeutics stock.
An article analyzes the future prospects of CRISPR Therapeutics stock, questioning whether its current valuation is sustainable or if its potential will be realized.